Results 271 to 280 of about 1,213,487 (359)

Methylation and gene expression patterns in adamantinomatous craniopharyngioma highlight a panel of genes associated with disease progression-free survival. [PDF]

Front Endocrinol (Lausanne)
Marrero-Gutiérrez J, Bueno AC, Martins CS, Silva-Júnior RMP, Dos Santos AC, Santos MV, Wildemberg LE, Antunes XLDS, Gadelha MR, Moreira AC, Vêncio RZN, Antonini SRR, de Castro M.   +12 more
europepmc   +1 more source

ATG4B is required for mTORC1‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer

FEBS Open Bio, EarlyView.
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan, Bethany C. Guerra, Selina Uranga, Jessica M. Cardin, Steven E. Riechman, Mariana Janini Gomes, James D. Fluckey   +6 more
wiley   +1 more source

The association between neutrophil percentage to albumin ratio and progression-free survival and overall survival in colorectal cancer patients: a retrospective cohort study. [PDF]

Front Nutr
Xie H, Wei L, Tang S, Gan J.
europepmc   +1 more source

Age‐Related Changes in Myeloid Cells and Their Impact on Subcutaneous Melanoma Growth in Mice

Aging and Cancer, EarlyView.
Our findings reveal that age‐related changes in subcutaneous melanoma growth and immunotherapy response are context‐dependent. In models where tumor growth and treatment resistance increase with age, this effect is partly driven by enhanced immunosuppression from myeloperoxidase‐active Gr‐1⁺ myeloid cells.
Kaitlyn M. Landreth, Dylan D. Thomas, Remi Nohoesu, Angisha Basnet, F. Heath Damron, Mary Garland‐Kledzik, Emel Sen Kilic, Tracy W. Liu   +7 more
wiley   +1 more source

Preoperative CT-based radiomics nomogram for progression-free survival prediction in pediatric posterior mediastinal malignancies. [PDF]

Front Oncol
Bi S, Chen C, Yu J, Yang T, Sun J, Hu Z, Zeng Q, Peng Y.   +7 more
europepmc   +1 more source

Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC)

, 2012
Roberto Iacovelli, Matteo Santoni, Giuseppe Di Lorenzo, Linda Cerbone, Massimo Aglietta, Cristina Masini, Maria Olga Giganti, Caterina Messina, Cora N. Sternberg, Giuseppe Procopio   +9 more
openalex   +1 more source

Cystic Ovarian Teratoma: Clinical and Radiographic Insights Into Chronic Pelvic Pain

Aging and Cancer, EarlyView.
An incidental benign mature cystic ovarian teratoma on imaging and discuss common imaging modalities. ABSTRACT In this case report, we present the clinical course of an 88‐year‐old woman with chronic pelvic pain attributed to an incidental benign mature cystic ovarian teratoma on imaging and discuss common imaging modalities and discussions with ...
Hashim U. Ali, Fahad H. Malik, Mohammad M. Zia, Ashar Ahmed, Mahfujul Z. Haque, Masood Siddiqui   +5 more
wiley   +1 more source

CT-radiomics combined with inflammatory indicators for prediction of progression free survival of resectable esophageal squamous cell carcinoma. [PDF]

Sci Rep
Wang Y, Bai G, Huang M, Chen W.
europepmc   +1 more source

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source

Extended progression-free survival after combination treatment with anlotinib and S-1 in refractory advanced esophageal cancer: A case report. [PDF]

Mol Clin Oncol
Yang J, Liu C, Liu L, Yang K.
europepmc   +1 more source